120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
MicroPulse经巩膜睫状体光凝治疗早中期青光眼：11眼一年随访病例系列和文献综述
Received 8 October 2025
Accepted for publication 22 January 2026
Published 28 January 2026 Volume 2026:20 569880
DOI https://doi.org/10.2147/OPTH.S569880
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Scott Fraser
Liu Li, Yingjie Li
Department of Ophthalmology, Nanchang First Hospital, Nanchang, Jiangxi Province, 330008, People’s Republic of China
Correspondence: Yingjie Li, Department of Ophthalmology, Nanchang First Hospital, Nanchang, 330008, People’s Republic of China, Email xljlyj@163.com
Purpose: To assess the efficacy and safety of MicroPulse Transscleral Cyclophotocoagulation (MP-TSCPC) in Chinese patients with early to moderate glaucoma over a one-year follow-up.
Patients and Methods: This retrospective case series included 11 eyes of 11 consecutive Chinese patients with early to moderate glaucoma who underwent MP-TSCPC between November 2023 and March 2024. All patients were aged 18– 80 years, had a baseline intraocular pressure (IOP) ≥ 21 mmHg, and completed at least 12 months of follow-up. MP-TSCPC was performed using an Iridex Cyclo G6 laser with standardized settings (2000 mW power, 31.3% duty cycle, 160 seconds total). Changes in IOP, the number of anti-glaucoma medications, best-corrected visual acuity (BCVA), surgical success rates, and complications were recorded.
Results: At 12 months, mean IOP decreased significantly from 28.64± 12.18 mmHg to 18.09± 7.70 mmHg (P< 0.05), and the mean number of anti-glaucoma medications was reduced from 3.27± 0.91 to 1.64± 1.00 (P< 0.01). BCVA remained stable throughout follow-up. No severe complication occurred, transient mild anterior chamber inflammation resolved with treatment.
Conclusion: Despite the small cohort size, MP-TSCPC demonstrates preliminary efficacy and good safety profile in IOP control in Chinese patients with early to moderate glaucoma, significantly lowering IOP and reducing medication burden without negatively impacting visual acuity or causing serious complications.
Keywords: intraocular pressure reduction, anti-glaucoma medication burden, surgical safety profile, treatment efficacy, Chinese patient cohort
Department of Ophthalmology, Nanchang First Hospital, Nanchang, Jiangxi Province, 330008, People’s Republic of China
Correspondence: Yingjie Li, Department of Ophthalmology, Nanchang First Hospital, Nanchang, 330008, People’s Republic of China, Email xljlyj@163.com
Purpose: To assess the efficacy and safety of MicroPulse Transscleral Cyclophotocoagulation (MP-TSCPC) in Chinese patients with early to moderate glaucoma over a one-year follow-up.
Patients and Methods: This retrospective case series included 11 eyes of 11 consecutive Chinese patients with early to moderate glaucoma who underwent MP-TSCPC between November 2023 and March 2024. All patients were aged 18– 80 years, had a baseline intraocular pressure (IOP) ≥ 21 mmHg, and completed at least 12 months of follow-up. MP-TSCPC was performed using an Iridex Cyclo G6 laser with standardized settings (2000 mW power, 31.3% duty cycle, 160 seconds total). Changes in IOP, the number of anti-glaucoma medications, best-corrected visual acuity (BCVA), surgical success rates, and complications were recorded.
Results: At 12 months, mean IOP decreased significantly from 28.64± 12.18 mmHg to 18.09± 7.70 mmHg (P< 0.05), and the mean number of anti-glaucoma medications was reduced from 3.27± 0.91 to 1.64± 1.00 (P< 0.01). BCVA remained stable throughout follow-up. No severe complication occurred, transient mild anterior chamber inflammation resolved with treatment.
Conclusion: Despite the small cohort size, MP-TSCPC demonstrates preliminary efficacy and good safety profile in IOP control in Chinese patients with early to moderate glaucoma, significantly lowering IOP and reducing medication burden without negatively impacting visual acuity or causing serious complications.
Keywords: intraocular pressure reduction, anti-glaucoma medication burden, surgical safety profile, treatment efficacy, Chinese patient cohort